Steps forward, backward, and sideways: Canada's bill on exporting generic pharmaceuticals

Area of Science:

• Pharmaceutical policy
• Intellectual property law
• Global health trade

Background:

• Bill C-9, passed in May 2004, amended Canada's Patent Act concerning compulsory licensing of patented pharmaceuticals.
• This legislation enables generic drug production and export for countries lacking manufacturing capacity, implementing a World Trade Organization (WTO) Decision.

Discussion:

• The article analyzes the legislative process and outcomes of Bill C-9.
• It examines the influence of civil society organizations in shaping the bill.
• Critiques are presented regarding the bill's shortcomings and its deviation from a "model" legislation.

Key Insights:

• Canada became the first nation to legislate a WTO Decision on pharmaceutical patent flexibilities.
• The bill allows for compulsory licensing and export of generic pharmaceuticals.
• Despite improvements, the final legislation contains significant flaws.

Outlook:

• The experience with Bill C-9 offers lessons for other countries implementing the WTO Decision.
• Recommendations are provided to avoid replicating the negative aspects of Canadian legislation.
• The article serves as a case study for pharmaceutical policy reform and global health advocacy.